Lonapegsomatropin
- Generic Name
- Lonapegsomatropin
- Brand Names
- Skytrofa, Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1934255-39-6
- Unique Ingredient Identifier
- OP35X9610Y
- Background
Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to insufficient growth hormone secretion. Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.
Lonapegsomatropin was granted FDA approval on 25 August 2021. It was later approved by the European Commission on 13 January 2022.
- Indication
In the US, lonepegsomatropin is indicated in the treatment of growth failure due to inadequate growth hormone secretion in patients one year and older who weigh at least 11.5 kg. In Europe, lonepegsomatropin is indicated to treat growth failure in children and adolescents aged from three years up to 18 years due to insufficient endogenous growth hormone secretion or growth hormone deficiency.
- Associated Conditions
- Growth Failure
- Associated Therapies
- -
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Ascendis Pharma submits sBLA for growth hormone deficiency therapy
Ascendis Pharma submits FDA application for expanded use of Skytrofa
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to ...
Ascendis Pharma A/S American Depositary Shares
Ascendis raised to outperform by Oppenheimer ahead of drug launch
Oppenheimer upgrades Ascendis Pharma shares on potential drug launches
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.